Saturday 17 October 2026
Export SPRC’s income statement to Excel — free account
SciSparc Ltd.
SPRC Healthcare Biotechnology
SciSparc Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $856,000.00, down 34.5% from fiscal 2024. Operating cash flow growth for three consecutive years.
1.70
0.30
−15.00%
Follow SPRC
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 0.00 | 2,997.54 | 529.20 | 37.23 | 11.25 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 41,769.00 | 34,791.12 | 6,535.62 | 1,281.42 | 338.31 | |||||
| People | |||||||||||||||
| People | Employees | 8 | 12 | 11 | 11 | 3 | 4 | 4 | 4 | 3 | 3 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 | 0.72 | 0.44 | 0.29 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 3 | 1 | 1 | ||||
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.10 | 76.28 | 38.74 | 73.71 | |||||
| EBT | (2) | (6) | (7) | (4) | (4) | (6) | (3) | (6) | (7) | (13) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (191.39) | (203.58) | (573.20) | (1,467.76) | |||||
| Net income | (2) | (6) | (9) | (5) | (4) | (6) | (3) | (6) | (7) | (13) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,496.67 | 1,308.64 | 42.40 | 6.89 | ||||
| Earnings | (2.14) | (2.14) | (838,054.10) | (381,245.90) | 66,305.88 | (13,899.68) | (2,784.85) | (2,728.63) | (242.04) | (98.07) | |||||
| Cash flow | (1.57) | (1.57) | (2.04) | 0.00 | (43,070.00) | (12,652.50) | (8,796.67) | (2,675.91) | (165.71) | (33.31) | |||||
| Capex | 0.00 | (0.01) | 0.01 | 0.00 | 0.00 | (87.50) | (5,410.00) | 0.00 | 0.26 | 0.00 | |||||
| Free cash flow | (1.58) | (1.58) | (2.03) | 0.00 | (43,070.00) | (12,740.00) | (14,206.67) | (2,675.91) | (165.45) | (33.31) | |||||
| Book value | 0.61 | 2.87 | 0.02 | 0.00 | 14,300.00 | 20,352.50 | 7,165.56 | 4,357.73 | 290.23 | 41.44 | |||||
| Shares, m | 1 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | — | — | 1,959.13 | 496.49 | 27.50 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | (975.28) | (254.15) | (30.72) | (5.68) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (1) | (5) | (7) | (5) | (4) | (5) | (8) | (6) | (5) | (4) | ||||
| Capex | 0 | 0 | 0 | 1 | — | 0 | (5) | — | 0 | — | |||||
| Free cash flow | (1) | (5) | (7) | (4) | (4) | (5) | (13) | (6) | (5) | (4) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 0 | 8 | (2) | 0 | 1 | 8 | 0 | 5 | 6 | 3 | ||||
| Total debt | — | — | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Net debt | (1) | (9) | 0 | (1) | (2) | (7) | (4) | (5) | (6) | (4) | |||||
| Shareholders’ equity | 1 | 8 | 0 | 0 | 1 | 8 | 6 | 10 | 9 | 5 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (320.16) | (115.51) | (120.67) | (167.80) | (187.46) | (92.79) | (25.26) | (47.02) | (58.38) | (135.56) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (284.76) | (182.24) | (88.98) | (153.49) | (586.74) | |||||
| ROE | (44.48) | (139.34) | (201.35) | (10,536.26) | (482.27) | (120.97) | (35.53) | (63.88) | (67.84) | (172.92) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · fundamentals updated 2 Oct 2026
Charts ten years each
SciSparc Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MLEC Moolec Science SA | $1.4M | — (loss-making) | — (loss-making) | +948.39% (above 0%: growing) | n/m | +4.48% (above 0%: growing) | (25.52%) | (77.92%) | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.3× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SPRC SciSparc Ltd. | $1.2M | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | |
| CYTOF Altamira Therapeutics Ltd. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +85.35% (above 0%: growing) | (157.79%) | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | −12.97% (below 0%: shrinking) | — | 0.00% | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CRIS Curis, Inc. | $1.1M | — (loss-making) | — (loss-making) | −65.98% (below 0%: shrinking) | n/m | −20.44% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MNTRQ 9 Meters Biopharma, Inc. | $1.0M | — (loss-making) | — | −25.99% (below 0%: shrinking) | n/m | +0.01% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ZVSA ZyVersa Therapeutics, Inc. | $970.0K | — (loss-making) | — | — | n/m | +54.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $1.1M | — | — | +4.16% | — | +25.28% | 0.00% | 0.00% |
SciSparc Ltd. (SPRC) key facts
- Concern: SciSparc Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $856,000.00, down 34.5% from fiscal 2024.
- SciSparc Ltd. (SPRC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SPRC traded at $1.70, a market capitalization of $1.2 million.
- Return on equity was −172.9% and debt-to-equity 0.24.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −18.65 (distress zone) for fiscal 2025.